Pretrial Clashes Intensify In Neurontin Off-Label MDL

By Jacqueline Bell

Law360, New York (February 11, 2010, 6:55 PM ET) -- With a trial in multidistrict litigation over Pfizer Inc.'s alleged off-label marketing of Neurontin barely more than a week away, the drugmaker is seeking depositions related to a Web site owned by plaintiff Kaiser Foundation Health Plan Inc. that Pfizer argues actually touts the drug’s off-label uses.

In at least two separate deposition battles ahead of a Feb. 22 trial, Pfizer contends that Kaiser's health care Web site recommends a generic version of Neurontin for the very conditions Kaiser argues the epilepsy drug is ineffective at...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles